
WHAT IS CLAIMED IS:

1. A compound of formula (I):




(I);

or a pharmaceutically acceptable salt thereof; wherein:

R^1 is aryl or heteroaryl, wherein the aryl and the heteroaryl are optionally substituted with one, two, three, four, or five substituents independently selected from C_1-C_3alkyl, C_2-C_4alkenyl, C_2-C_4alkynyl, amino, aminoC_1-C_3alkyl, C_3-C_4cycloalkyl, halo, haloC_1-C_3alkyl, hydroxy, and hydroxyC_1-C_3alkyl;

R^2 and R^3 are independently selected from hydrogen, C_1-C_3alkoxy, C_1-C_3alkyl, cyano, halo, haloC_1-C_3alkyl, and hydroxy;

R^4 is selected from:




; and ; wherein

R^a is hydrogen or C_1-C_3alkyl; and

denotes the point of attachment to the parent molecular moiety;

R^5 is selected from the group consisting of:



wherein q, r, and d are each independently 0 or 1; and wherein R^x, R^y, and R^p are independently selected from C_1-C_3alkoxy, C_1-C_3alkyl, halo, haloC_1-C_3alkyl, and hydroxy; and

wherein  denotes the point of attachment to the parent molecular moiety.


2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^2 and R^3 are each halo.

3. The compound of claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein R^1 is substituted, and wherein one of the substituents on R^1 is haloC_1-C_3alkyl.

4. The compound of any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein R^1 is naphthyl, wherein the naphthyl is optionally substituted with one, two, or three groups independently selected from C_1-C_3alkyl, C_2-C_4alkynyl, C_3cycloalkyl, halo, and hydroxy.

5. The compound of any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein R^1 is phenyl, wherein the phenyl is optionally substituted with one or two groups selected from C_1-C_3alkyl, C_3-C_6cycloalkyl, halo, and haloC_1-C_3alkyl.


6. The compound of any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein R^1 is



;

wherein ~~~ denotes the point of attachment to the parent molecular moiety.


7. The compound of any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein R^1 is



;

wherein ~~~ denotes the point of attachment to the parent molecular moiety.

8. The compound of any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein R^1 is



;


wherein

q is 1, 2, or 3;

each R^z is independently selected from C_1-C_3alkyl, and halo; and

~~~ denotes the point of attachment to the parent molecular moiety.

9. The compound of any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein R^1 is
~~~



;

wherein

q and r are each independenty 0 or 1;

R^x and R^y are independently selected from C_1-C_3alkoxy, C_1-C_3alkyl, halo, haloC_1-C_3alkyl, and hydroxy; and


denotes the point of attachment to the parent molecular moiety.

10. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein


R^2 is hydrogen;

R^3 is fluoro;


R^1 is selected from



;




; and



; and

R^5 is



; wherein


denotes the point of attachment to the parent molecular moiety.

11. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein


R^2 is chloro;

R^3 is fluoro;

R^1 is selected from




; ; ;



; and ; and


R^5 is selected from



; wherein

~~~ denotes the point of attachment to the parent molecular moiety.


12. The compound of claim 1 of formula (II):




(II);

or a pharmaceutically acceptable salt thereof, wherein:

R^1 is selected from
~~~




; ; and



;

wherein  denotes the point of attachment to the parent molecular moiety; and

R^4 is selected from:




; ; ; ; ; ; ; ; and ;

wherein

R^a is hydrogen or C_1-C_3alkyl; and















 denotes the point of attachment to the parent molecular moiety.
















13. A compound selected from:



; ; ;

; ; ;





;

;

,

isomer 1;
, isomer 2;

;

;;

;

;

;

;

;

;

;

;





;

;

;

;

;

;

;

;

;

;

;

;

;

;

;




;



;



;



;

;

;


;

;

;



;

;

;


isomer 1;

isomer 2;



isomer 3;

isomer 4;




isomer 1;




isomer 2;




isomer 3;




isomer 4;




isomer 1;




isomer 2;





isomer 1;





isomer 2;



;


;


;


; and


;

or a pharmaceutically acceptable salt thereof.

14. A pharmaceutical composition comprising a compound of any one of claims 1 to 13, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.

15. A compound of any one of claims 1 to 13, or a pharmaceutically acceptable salt thereof for use in treating a cancer susceptible to KRAS G12D inhibition in a subject in need thereof.

16. A compound of any one of claims 1 to 13, or a pharmaceutically acceptable salt thereof for use in treating cancer expressing KRAS G12D mutation in a subject in need thereof.

17. A compound of any one of claims 1 to 13, or a pharmaceutically acceptable salt thereof for use in treating cancer in a subject in need thereof, wherein the cancer is pancreatic cancer, colorectal cancer, lung cancer and/or gastric cancer.